Editorial policy

Sources. Every factual claim links to its source. We prioritize FDA, PubMed, ClinicalTrials.gov, peer-reviewed journals and primary press releases. When we rely on a secondary source, we link to it.

Checks. Each story is checked against its cited sources before it’s published. U.S. regulatory status is checked on the day of publication, and the date appears on the page. Status can change after that date.

What our labels mean.

• FDA-approved: the FDA approved a specific product for the uses on its label. That doesn’t extend to compounded versions or other uses.
• Compounded versions, not FDA-approved: made by a pharmacist or physician for an individual patient. Compounded drugs are not FDA-approved, which means the FDA doesn’t review their safety, effectiveness or quality before they’re marketed.
• Investigational: being studied in people, and not FDA-approved for that use.
• Animal studies only: we found no published human studies as of the date we checked.
• Not FDA-approved: no FDA approval, and none of the other labels applies.

What we don’t publish. We don’t publish doses, cycles or reconstitution steps for unapproved peptides. For approved medicines, we point to the FDA label and a clinician. We don’t promise cures or results, and we don’t publish before-and-after claims. We don’t link to or recommend “research use only” or gray-market sellers for human use.

Who writes this. Stories carry the byline of the Best Peptides Today Editorial Team. We use AI tools to help research, write and check our pages. A “Reviewed by” line appears only when a named person actually reviewed the page, with the date.

Corrections. When we find an error, we correct the page, update its date and list it on our corrections page.

Commercial relationships. Any commercial relationship is disclosed clearly, next to the content it touches.